Qualigen Therapeutics, Inc. announces that a poster featuring the Company's pan-RAS inhibitor program in pancreatic cancer will be presented as part of the Scientific Program at the American Society of Clinical Oncology's (ASCO) 2023 Annual Meeting held June 2-6, 2023 in Chicago. The poster outlines results of concurrent administration of the Company's pan-RAS inhibitor molecules with commonly used therapeutics against pancreatic cancer. In vivo activity was confirmed in xenograft experiments with cell lines and PDX models, and the molecules were shown to co-operate with AMG-510 (sotorasib) (G12C specific inhibitor) and MRTX1133 (G12D specific inhibitor) against pancreatic cancer cell lines.

The agents were also shown to suppress resistance to MRTX1133 in vitro, which led authors to believe these pan-RAS compounds may overcome resistance to AMG-510 and MRTX1133 in vivo. The Company had two abstracts accepted to the meeting, the other of which is “A novel pan-RAS inhibitor for luminal B breast cancer.”Tariq Arshad, Howard Donninger, Mike Sabo, John Trent, Geoffrey J. Clark, Joe Burlison. This abstract can be found in the ASCO 2023 Annual Meeting Abstract Book.

Qualigen's pan-RAS inhibitor platform is a family of small molecules designed to prevent mutated RAS gene proteins from binding to their effector proteins. Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to impact tumor growth in multiple in vivo models. Qualigen is evaluating promising compounds generated from this partnership in various RAS-driven advanced solid tumors such as pancreatic, breast, colorectal, and lung cancers.